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The requirement of an independent verification of the monitor units MU or time calculated to
deliver the prescribed dose to a patient has been a mainstay of radiation oncology quality assurance.
The need for and value of such a verification was obvious when calculations were performed by
hand using look-up tables, and the verification was achieved by a second person independently
repeating the calculation. However, in a modern clinic using CT/MR/PET simulation, computerized
3D treatment planning, heterogeneity corrections, and complex calculation algorithms such as
convolution/superposition and Monte Carlo, the purpose of and methodology for the MU verifica-
tion have come into question. In addition, since the verification is often performed using a simpler
geometrical model and calculation algorithm than the primary calculation, exact or almost exact
agreement between the two can no longer be expected. Guidelines are needed to help the physicist
set clinically reasonable action levels for agreement. This report addresses the following charges of
the task group: 1 To re-evaluate the purpose and methods of the “independent second check” for
monitor unit calculations for non-IMRT radiation treatment in light of the complexities of modern-
day treatment planning. 2 To present recommendations on how to perform verification of monitor
unit calculations in a modern clinic. 3 To provide recommendations on establishing action levels
for agreement between primary calculations and verification, and to provide guidance in addressing
discrepancies outside the action levels. These recommendations are to be used as guidelines only
and shall not be interpreted as requirements. © 2011 American Association of Physicists in Medi-
cine. DOI: 10.1118/1.3521473Key words: quality assurance, monitor unitsTABLE OF CONTENTS
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I. INTRODUCTION
The delivery of therapeutic radiation is a medical procedure
and as such requires independent confirmation to ensure cor-
rect and accurate delivery. This confirmation is accomplished
by a comprehensive calculation and chart review procedure
performed both before and throughout patient treatment.1–4 AMedical Physics, Vol. 38, No. 1, January 2011key component of this procedure, and the focus of this re-
port, is the “independent monitor unit verification,” where
the monitor unit MU setting determines the quantity of
radiation delivered to the patient. In this report, the “primary
MU” refers to the calculation used for the actual treatment of
the patient, while “MU verification” MUV refers to a mea-
surement or calculation that is performed only for the pur-
pose of confirming the primary MU calculation and is not
used for the delivery of radiation. Consistent with other
American Association of Physicists in Medicine Task
Groups,1,5 the MUV is considered to be an independent
check of the dose or machine setting at one point and is a
separate activity distinct from the treatment plan review, with
its own assessment of the veracity of the factors that are used
in the check. While these settings are generically referred to
as “monitor units” in this report, this term also applies to
time settings for treatment units that employ radioactive
sources.
Radiation therapy has changed significantly over the past
years. In the past, both primary and verification calculations
were performed using manually derived and entered data,
and the need for a check was obvious in order to identify
transcription errors, depth misreadings, or the incorrect
look-up of a table parameter. A second person independently
verified the patient information such as source to surface
distance SSD and depth, parameters such as TMR and out-
put factor, and the calculation arithmetic. Agreement be-
tween the MUV and the primary MU calculations to within a
set tolerance was easily achieved due to the application of
almost identical methods for both calculations.
The introduction of extensive computerization, volumetric
imaging, and improved computation algorithms has changed
both the complexity of the patient treatment and the manner
in which MUV is performed. Most MUV calculations are
performed today by computer programs using electronic data
transfer protocols, which are much less likely to result in the
arithmetic, transcription, or look-up errors that the traditional
verification calculation was designed to find. Modern treat-
ment planning systems TPSs, which use sophisticated algo-
rithms and build 3D geometrical patient models complete
with heterogeneous tissue densities, are complex. This com-
plexity presents challenges to traditional manual verification
methods since much of the information required to perform
the verification needs to come directly from the TPS.
These changes have brought into the question the value of
performing the MUV. There has been anecdotal speculation
whether any further checks should be required for a planning
system which has been carefully and thoroughly commis-
sioned and passed a series of quality assurance QA tests. A
physicist’s time is a limited resource in a busy radiotherapy
department, and performing a verification of every calcula-
tion for every patient can be time consuming and a major
drain on this resource. It is critical to evaluate the procedures
that are performed to ensure that they are not only necessary
but also effective. These types of questions are best ad-
dressed by identifying both the value and the limitations of
the MUV in the modern clinic; such an assessment by this
task group is provided in Secs. II and III in the context of
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that the MUV remains a useful and necessary step in assur-
ing safe and accurate patient treatment and discusses aspects
of an MUV program in Sec. IV.
The clinical physicist needs guidelines for acceptability of
agreement between the primary and verification calculations.
In the days of 2D and manual primary calculations, essen-
tially perfect agreement was expected since a virtually iden-
tical methodology was repeated for the MUV calculation.
Now, with the use of different algorithms that may incorpo-
rate different approximations for both the patient and the
beam parameters, the acceptable level of agreement that can
be expected is unclear. This is further complicated by the fact
that the verification algorithm is usually simpler, and there is
a tendency to attribute large discrepancies to the simplicity
of the algorithm.6 While larger discrepancies may be ex-
pected, procedures and guidelines should be established to
eliminate, as much as practical, sources of discrepancies, and
methodologies should be established to resolve the larger
discrepancies. Section VI provides suggested guidelines for
establishing agreement action levels, as well as remedial ac-
tions that can be undertaken if the difference between the
primary MU calculation and the MUV exceeds these levels.
Given this environment, the present task group was
formed to:
1 Re-evaluate the purpose and methods of the “indepen-
dent second check” for monitor unit calculations for
non-intensity modulated radiation therapy IMRT treat-
ment in light of the complexities of modern-day treat-
ment planning.
2 Present recommendations on how to perform MUVs in a
modern clinic.
3 Provide recommendations on establishing action levels
for agreement between primary calculations and verifi-
cation, and to provide guidance in addressing discrepan-
cies outside the action levels. These recommendations
are to be used as guidelines only and shall not be inter-
preted as requirements.
This report does not address or apply to the verification of
IMRT calculations. The AAPM has created a separate work-
ing group on IMRT to consider IMRT verification and other
IMRT-related issues.
II. OBJECTIVE OF THE VERIFICATION
CALCULATION
The goal of the MUV is to ensure that the primary moni-
tor unit calculation is sufficiently accurate for the safe and
effective treatment of the patient. While the accuracy and
safety of the primary calculation system, typically a TPS, is
verified to a large extent by a thorough and complete set of
acceptance and commissioning tests, it is recognized that
most centers do not have the resources to perform a compre-
5hensive set of tests on their own. It was recognized by other
Medical Physics, Vol. 38, No. 1, January 2011task groups that commissioning tests, designed to establish
the accuracy limits of the system, cannot test the system
under all possible current and future clinical scenarios;5 this
is particularly evident given the increased functionality and
complexity added to planning systems in the past few years.
Typically commissioning tests only cover the existing prac-
tices at a particular center. Subtle changes in process could
lead to the use of the untested modules within the TPS or
usage in a manner that was not originally tested. These limi-
tations necessitate the performance of a MUV to ensure ap-
propriate dose delivery in each instance of a TPS calculation.
There are a number of specific incidents that point to the
value of a MUV. For example, in 2006, a patient received a
fatal radiation overdose due to the introduction of electronic
data transfer between the electronic patient chart, the TPS,
and the treatment delivery system. Electronic data transfer
was adopted for most treatment sites, with the exception of
some specialized and infrequently used techniques; a manual
MU calculation based on a particular plan normalization
style was used for the treatment even though the TPS gener-
ated plan used a different normalization. The investigation
into this event indicated that an independent calculation
check may have identified the resulting overdose prior to
treatment.7 In France, between 2004 and 2005, 23 patients
received an overexposure of radiation resulting from the in-
troduction of the enhanced dynamic wedge into the clinic;8 a
review of the incident pointed to the recent elimination of an
independent check of the MU calculation as a major contrib-
uting factor. A similar deficiency in procedure was identified
in an incident in Panama in 2000, where 28 patients were
overexposed to radiation due to the incorrect usage of the
TPS. An International Atomic Energy Agency IAEA re-
view of the incident9 included among its recommendations:
“Results provided by the TPS need to be checked, and this
should include verification by manual calculation of the
treatment time and dose to the selected point. This verifi-
cation should be part of the QA programme.”
The IAEA, in a review of radiotherapy mistreatments10
prior to these events, concluded, in part, that an independent
verification of the treatment unit settings was an important
element required to ensure patient safety. More recent re-
views of radiotherapy treatment errors support this assess-
ment through an acknowledgment that the complexity of
modern TPSs leads to a larger opportunity for mistreatment
and misuse, which is best guarded against through a set of
rigorous QA procedures. The ICRP, in a 2009 report aimed at
preventing exposure errors from new treatment technologies,
states “A simple secondary MU calculation, independent
from the TPS, has proven for many years to be an efficient
tool for prevention of major errors in dose delivery.”11 These
reviews of incidents all point out that checks such as MUV
are important for patient safety.
An effective MUV is one of the several tools in the QA
process designed to catch gross errors in the treatment dose
delivery for an individual patient. An evaluation of the inci-
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cancer center concluded that treatment plan checks, includ-
ing MU verification calculations, were very effective in de-
tecting documentation and treatment planning errors.12 The
types of errors most likely to occur in a particular center will
vary with staffing and process details. The responsible physi-
cist at each center is the person best suited to assess the type
of errors that can occur during the planning and delivery
process. The physicist should ensure that the MU verification
process effectively detects the most probable causes of gross
errors and utilizes reasonable action levels for disagreement
between primary calculations and the verification check. This
responsibility extends to maintaining clear documentation
and providing periodic training for staff in all disciplines that
are required to review and understand the MUV, including
both the limitations of the calculation and the established
action levels for this QA activity.
II.A. Types of error
A verification calculation necessarily will generate results
that vary from the primary calculation. Small differences on
the order of a few percent do not necessarily indicate an error
in the primary calculation. Such discrepancies may result
from differences in algorithms, in geometrical patient repre-
sentation, or in small variations in beam data. Larger differ-
ences, however, may be a symptom of an error. While there
are too many sources of potential error in monitor unit cal-
culations to compile a comprehensive list, it is useful to clas-
sify errors into two broad types, here referred to as random
and systematic errors. This classification will help in identi-
fying when these errors occur and minimizing the chances
for their occurrence.
A random error is not reproducible, by its very definition.
If the calculation is repeated, especially by a different per-
son, the error is likely to be detected. Examples of random
errors are incorrect beam energy, wrong dose, manual arith-
metic calculation errors, incorrect dosimetric data retrieval
from a table, incorrect bolus thickness characterization, and
incorrect manual transcription of field size. Random errors
can effectively be reduced by a MUV calculation. The
chance of the same random error repeating itself in both the
primary and the verification calculation is, by definition, ex-
tremely small.
The second category of error is due to systematic causes,
generally attributed to a defect in part of the calculation
procedure.13 There is a correlation between the circumstance
in which it occurs and its chance of occurrence. The error
will likely occur again for the same calculation even if per-
formed by a different person. One class of systematic errors
results from misunderstanding of standard procedures; for
example, the misinterpretation of plan dose normalization or
beam calibration designation e.g., depth of dm vs 10 cm,
SSD vs SAD. Other examples of systematic errors are an
incorrect entry in the tissue phantom ratio TPR table used
for calculation, an error in the standard form for a manual
calculation, and an algorithmic error in, or misapplication of,
Medical Physics, Vol. 38, No. 1, January 2011the software used in monitor unit calculations. The effective-
ness of identifying systematic errors through a verification
check that is comprised of repeating the same calculation by
an independent person is more limited than for random er-
rors; rather, the use of a different calculation program/
algorithm or a measurement is more likely to find such an
error. Systematic errors are best reduced by a thorough re-
view of the process, a careful commissioning procedure, and
complete and accurate data tables. An external audit of the
clinic’s process, such as performed by the Radiologic Phys-
ics Center for institutions involved in NCI-funded protocols
or offered by M.D. Anderson’s Radiation Dosimetry Services
for beam calibration, is recommended as a further method to
reduce systematic errors.
An error that occurs in the course of a MU calculation
might be either random or systematic, depending on the pro-
cess. For example, the SSD can be erroneously reported and
used by a planning system due to some thermoplastic mask
material stretching across an air space. If the standard proce-
dure of the institution includes a step to use tools within the
planning system to check the automatically detected SSD
and this step was missed, then a random error has occurred.
However, if the standard procedure does not include such a
check before the MU calculation, this would be a systematic
error in the treatment planning process.
The increasing use of computer programs for MU calcu-
lations will shift certain types of errors from random to sys-
tematic. It is highly unlikely that after appropriate commis-
sioning, a computer program will incorrectly look-up data at
random, download a wrong field size intermittently, and
make other similar errors. This does not mean that comput-
erized MU calculations will generate error-free results; vir-
tually all programs contain coding errors and are built around
assumptions of usage that can potentially lead to an incorrect
result. The pattern and procedures that give rise to anoma-
lous results can provide information that can isolate the un-
derlying cause of the problem, which could be a code logic
error, a data or database error, or inappropriate program use.
II.B. Potential errors
The level of radiotherapy computer systems connectivity
present in an institution plays a critical role in the frequency
and type of error that may occur. This interplay of connec-
tivity and error frequency is illustrated in Table I, which lists
some common errors encountered in the past and rates their
occurrence probability according to connectivity. The con-
nectivity among CT-simulator, TPS, treatment chart, record–
and-verify system and treatment delivery systems including
block cutters are classified into three different groups:
1 Manual—no connectivity, all parameters for treatment
must be manually copied into a treatment chart with a
relatively high possibility of transcription errors.
2 Partial connectivity—connectivity between some sys-
tems, or only basic parameters are transferred, but some
508 Stern et al.: TG114 report 508manual data entries are required. Examples of required
adjustments include prescription, set MU, wedge orien-
tation, MLC shapes, and tray types and positions.
3 Full integration—complete transfer of all information
including custom shaping and wedge orientation. Ad-
justment of field parameters occurs only for clinically
based changes requested after the treatment has been
TABLE I. Likelihood of potential errors in MU calculation.
Potential error condition
Degree
Manual
1 Tray factors
a Leaving out tray Ha
b Using wrong tray H
2 Wedge factors
a Leaving out wedge H
b Wrong wedge H
c Wrong wedge direction for enhanced dynamic
wedge or for off-axis calculations H
d Off-axis in wrong direction e.g., along instead
of perpendicular to wedge gradient H
3 Not planning according to Rx
a Wrong energy H
b Wrong field size H
c Wrong beam weights H
d Wrong prescription dose H
4 Wrong depth M
5 Wrong equivalent square for open or blocked field
size M
6 Wrong SSD M
7 Calculation point too close to a field or block edge
e.g., in penumbra M
8 Wrong CT data set L
9 Incorrect automatic contouring of CT images,
including replacing sim table with treatment table L
10 Wrong density derivation from CT images M
11 Wrong scaling of CT/MR images L
12 Inconsistencies/errors in input data M
13 Errors arising from incorrect documentation of
treatment e.g., bolus not documented M
14 Errors arising from not changing defaults to actual
patient settings in treatment planning system e.g.,
energy, field size, machine M
15 Computer bugs M
16 Data transmission errors M
17 Data corruption M
18 Change to already approved plan M
19 Using untested area of treatment calculation system L
20 Calculating with wrong grid size too coarse, might
be especially a problem for electrons M
aH=high, M=medium, and L=low likelihood of potential error.planned.
Medical Physics, Vol. 38, No. 1, January 2011The majority of centers likely fall into category 2, with
many centers approaching category 3. In these environ-
ments, the probability of an event can be classified as low
L, medium M, or high H. Table I is a task group mem-
ber consensus analysis of typical events and is intended to be
used as an initial guide for centers performing their own
tomation
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lihood of encountering any particular error will strongly de-
pend on the details of the processes implemented at any spe-
cific center.
III. LIMITATIONS OF THE VERIFICATION
CALCULATION
The verification calculation is not and should not be used
as a check of the overall accuracy of the primary TPS; that is
the function of commissioning and continual QA. It is cru-
cial that both the primary and the verification planning sys-
tems be properly and thoroughly commissioned so that they
are as accurate as possible. Monitoring the agreement be-
tween the TPS and the verification system during clinical use
can aid in identifying regions where beam models or data
may be improved, but such monitoring is not a substitute for
the commissioning of either system. Both the TPS and the
verification system should be fully tested and commissioned
following accepted guidelines5,14,15 prior to clinical use.
A key result from commissioning tests is the establish-
ment of the expected accuracy of the primary TPS and MUV
system in clinically relevant situations. This provides the ba-
sis for the action levels that are set for the MU verification
calculation. TPS accuracy will be clinic-dependent and is
expected to vary with the complexity of the calculations. The
verification program is typically not as accurate as the pri-
mary TPS, particularly for complex geometries and/or het-
erogeneity corrections. Therefore, the agreement of the veri-
fication and primary calculations should be expected to vary
with the complexity of the situation. See Sec. VI for further
discussion of the expected agreement and action levels.
The MUV is not a check of the accuracy of the entire
calculated dose distribution. It only verifies that the monitor
units determined by the primary TPS will deliver the ex-
pected dose within acceptable uncertainty to a single point
within the treatment volume. That point may be the iso-
center, the prescription point, or some other well-defined
points see Sec. V A on the selection of the comparison
point. The commissioning and periodic check of the TPS
calculation algorithm must be relied upon to assure that the
accuracy at the comparison point implies accuracy through-
out the targeted tissues.
Since the verification is confined to checking the dose
calculation at a single point in the field, the verification by
itself does not constitute a complete QA plan review. The
MUV is only one part of a complete physicist’s plan review.
While many elements of a plan review are implicit in the
MUV, a careful review of all the plan parameters common to
the MUV must still be performed to ensure these data reflect
the actual patient treatment. Thus, in addition to the MUV,
the physicist’s plan review should confirm that the dose,
beam energy, fractionation, and dose point location are con-
sistent with the physician’s prescription. Other data such as
effective equivalent field can be estimated from the exposed
area seen in a DRR or MLC pattern. These and other ele-
ments common to both the physicist’s plan review and the
verification data, such as beam SSD, beam modifier identifi-
Medical Physics, Vol. 38, No. 1, January 2011cation, and orientation, need to be examined in the context of
the intended treatment to ensure that a systematic error in the
plan is not propagated to the MUV. In the event that the
difference between the MUV and primary calculation is out-
side the accepted action levels, the resolution of the discrep-
ancy should include a re-examination of the parameters used
in the calculation that are directly derived from the TPS.
IV. ASPECTS OF A MU VERIFICATION
PROGRAM
In most institutions, MU verification is performed using a
computer program or TPS different from the primary TPS,
although manual calculations may occasionally be used. The
verification program is usually, but not necessarily, less com-
plex than the primary TPS, using simpler calculation algo-
rithm and patient geometrical representation.
IV.A. MU verification and patient plan quality
assurance
The MUV is one component of a complete plan review
performed by a qualified medical physicist to ensure the
safety and efficacy of a treatment plan. The purpose of the
plan review is to ensure that the treatment plan is clinically
reasonable, that dosimetric calculations are correct, and that
the plan will deliver treatment as specified in the prescrip-
tion. Guidelines for plan checks are given in AAPM Task
Group 40 Ref. 1 and by the American College of
Radiology.3 This in-depth review should consider all ele-
ments of the treatment plan. The reviewer must verify that
correct parameters are used in MU calculations, and that cal-
culations are performed correctly as per the physician’s pre-
scription. The reviewer must also confirm that treatment
setup and delivery information are transcribed properly from
physician’s intent through simulation to treatment planning
and from treatment planning to the patient’s chart and/or the
record-and-verify system.
This task group recommends that the verification calcula-
tion should be completed prior to the delivery of the first
treatment fraction. In the rare occasion where this is not pos-
sible, the MUV should be performed as soon as possible,
consistent with the recommendations of TG-40: Prior to the
delivery of the third treatment fraction or 10% of the pre-
scribed dose, whichever corresponds to the least delivered
dose.
Each center performing after-hours emergency treatments
should have a policy detailing how planning, including the
MUV, is to proceed when a physicist is not immediately
available for plan and calculation review. The staff desig-
nated to calculate the treatment MU, usually the radiation
therapist or radiation oncologist, must be adequately trained
in the use of calculation software and/or dosimetry data
tables, and that data must be readily accessible. The MUV
should then be performed as soon as possible, preferably
before the next treatment but in any event conforming to the
recommendations of TG-40 stated above. This task group
also recommends the policy includes a maximum fractional
dose that may be delivered in emergency treatments prior to
510 Stern et al.: TG114 report 510a complete physics review and MUV, and suggests a value of
3–4 Gy. Finally, the policy should include periodic training
to maintain the competency of staff involved in after-hours
treatments.
MUV is an important part of the clinical physicist’s re-
sponsibilities, and adequate time must be allotted for this
task. Hospital and departmental administrators must provide
adequate physics staffing to allow for the timely completion
of patient plan QA checks, including the MUV, in conform-
ance with the TG-40 recommendations. Administrators are
referred to the ACR/AAPM Abt Study of Medical Physics
Work Values for Radiation Oncology Services16 for guide-
lines on these activities.
IV.B. Commissioning of a verification system
As with any system used in the clinical treatment of pa-
tients, the MUV system requires commissioning and ongoing
quality control monitoring to ensure the accuracy, safety, and
efficacy of the system. While the details of the commission-
ing process for a clinical dosimetric system are outside the
scope of this report, it is important to note that the MUV
system constitutes such a system and requires its own com-
prehensive commissioning.
For the purposes of commissioning, the MUV system
should undergo a testing procedure for conventional TPSs
such as has been recommended by others.5,14,15 Although
these reports focus on 3D TPSs, which typically have more
complex functionality than MUV systems, the core dosimet-
ric tests described are applicable to the commissioning of the
MUV system. The calculated dose resulting from a given
number of monitor units should be independently verified by
measurements and compared, if possible, with the results of
other established calculation systems of known accuracy,
such as institutional data previously validated by indepen-
dent measurement, RPC site visit, or other means. Commis-
sioning tests for the system should include clinically relevant
geometries that verify the accuracy of shaped field calcula-
tions and calculations in heterogeneous media if such situa-
tions are encountered in the clinical practice of the institu-
tion. This testing program should establish the accuracy of
the MUV system in different clinical situations, and this de-
termination should be used to establish action levels as de-
scribed in Sec. VI A of this report. Once commissioned, a
QA program should be implemented for continual surveil-
lance of the constancy of the system. Additional checks may
be done to ensure that the mathematical models and data
used for a given treatment machine model and beam energy
closely match available published data.
Other nondosimetric clinical functionalities within a
MUV system require commissioning as well. As with a con-
ventional TPS, the configuration and presentations of the
treatment unit geometry within a MUV system should un-
dergo specific testing. In particular, the crucial functionality
of plan data import and transfer needs to be carefully and
thoroughly tested to ensure the integrity and completeness of
the data passed between systems if it is to be used as part of
the clinical process.
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An “independent” check of the dose calculation is called
for by several professional groups.1,3 The meaning of “inde-
pendence,” however, has to be carefully considered in the
modern environment of sophisticated computer calculation
algorithms and direct communication between TPS, MUV
calculation systems, and treatment delivery systems.
In general, the independence of the MUV is established
by using a different methodology and/or program than that
used for the primary calculation.4 The only exception to this
principle applies to a manually calculated verification of a
primary manual calculation. An independent calculation can-
not be obtained by using the same program for both the
primary and the verification calculations. Even if a TPS has
more than one calculation model implemented, the use of a
separate program is strongly recommended over the use of a
different beam model within the same system because many
of the potentially errant parameters would be common to
both calculation models. The verification program typically
uses a different beam and/or patient model than the primary
TPS. In the case when the beam and patient models are simi-
lar, the algorithmic implementations should be different. This
is typical if the programs were developed by different ven-
dors.
The files containing beam data and parameters used by
the verification calculation program should be separate and
independent of the files used by the primary calculation,4
even if both sets of files are based on the same measured
data. This will aid in the identification of calculation errors
due to data errors either incorrect/inaccurate data or typo-
graphical mistakes as well as errors due to corruption of the
stored values.
The electronic transfer of patient treatment parameters
from the primary TPS to the verification program, either di-
rectly or via the record-and-verify system, is encouraged and
does not invalidate the independence of the verification cal-
culation. The chance of electronic transfer errors during
download is much less than the chance of manual entry tran-
scription errors. However, a careful examination of all the
transferred parameters is crucial to ensure that the data re-
flect an accurate description of the physical treatment condi-
tions and do not replicate an error such as an incorrectly
determined SSD/depth or dose artifact from poor calculation
point location. Whenever possible, parameters should be in-
dependently verified or determined from basic planning data,
such as extracting the field size and blocked equivalent
square from the beam’s eye view BEV and obtaining the
treatment depth independently of the CT image information.
For some parameters, such as radiological depth, only a
rough estimation may be possible. The effectiveness and in-
dependence of the MUV relies on the assurance that elec-
tronically transferred calculation parameters are indepen-
dently verified to accurately describe the treatment
conditions.
The MU verification calculation should be performed
preferably by an independent physicist or under physics su-
pervision by a qualified individual who is not involved in the
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planner who electronically transfers parameters from the pri-
mary TPS to the verification system and possibly even per-
forms the verification calculation itself. In such cases, a care-
ful review of both calculations must be done by an
independent physicist or under physics supervision by a
qualified individual who is not involved in the primary
calculation.17
IV.D. Potential advantages of a measurement-based
verification algorithm
While any valid dosimetric calculation system, up to and
including a second TPS or Monte Carlo simulation, can be
used to perform a verification MU calculation, there is a
potential benefit to using a simple measurement-based calcu-
lation system in which the effects of scatter, missing tissue,
and tissue heterogeneity are separated and can be indepen-
dently assessed. While a state-of-the-art TPS may provide a
very good simulation of the dose distribution, it must be
recognized that it is nonetheless a simulation using derived
parameters that can be quite separate from the original input
dosimetry measurements and can behave in unexpected
ways. A measurement-based verification algorithm balances
the complexity of the primary TPS with the transparency of a
calculation based directly on a set of simple measurements,
with a few well understood small perturbations applied to
account for patient geometry effects.
A system comprised of measured parameters, such as is
described in Appendix A, enables the physicist to decompose
a calculation and consider the impact of each factor on an
individual basis. Such an approach enables the physicist to
isolate the potential causes of a discrepancy, relate any in-
vestigative measurements to calculations, and thus aid in
TABLE II. Guidelines for action levels for disagreement between verification
Primary calculation geometry
Similar calcula
Same patient
geometry
%
Approx. p
geome
%
Minimal field shaping 2 2.5
Substantial field shaping and/or contour change 2.5 3
Wedged fields, off-axis 2 2.5
TABLE III. Guidelines for action levels for disagreement between verificatio
Primary calculation geometry
Similar ca
Same patient geome
%
Large field 2
Wedged fields, off-axis 2
Small field and/or low-density heterogeneity 3Medical Physics, Vol. 38, No. 1, January 2011identifying the underlying cause of the discrepancy. The ap-
proach may be limited, however, for very complex calcula-
tions involving heterogeneity corrections.
V. RECOMMENDED METHODS OF MU
VERIFICATION
The parameters and formalism used in the MUV depend
on several factors such as radiation type, beam energy, algo-
rithms used by the primary and verification calculation sys-
tems, irregularity of the treatment field, location of the com-
parison point within that field, the field-shaping device
blocks, MLC, use of different beam modifiers wedges,
compensators, etc., and the tissue heterogeneities. The treat-
ment machine normalization point plays a key role in the
MUV formalism. In addition, the attainable verification ac-
curacy is critically dependent on the selection of the com-
parison point within the field and patient geometry. Note that
while either an in-phantom dose measurement or an indepen-
dent calculation of the dose for a given MU or the MU re-
quired to deliver a particular dose can serve as a valid MUV,
the following discussion focuses primarily on the use of a
calculation methodology.
V.A. Comparison point selection
The appropriate placement and selection of a comparison
point is critical in achieving an accurate verification and,
consequently, achieving an agreement within the anticipated
limits listed in Tables II and III. It is recommended that
placement of the plan normalization point should follow
ICRU guidelines18,19 for dose reporting. Although preferable,
the MU verification point need not coincide with the plan
normalization point. It is sufficient, for verification purposes,
primary calculations for homogeneous conditions.
algorithms Different calculation algorithms
t Uniform cube
phantom approx.
%
Same patient
geometry
%
Approx. patient
geometry
%
Uniform cube
phantom approx.
%
3 2.5 3 3
4 3 3.5 4
3 3.5 4 5
primary calculations with heterogeneity corrections.
ion algorithms Different calculation algorithms
Approx. patient
geometry
%
Same patient
geometry
%
Approx. patient
geometry
%
3 2.5 3.5
3 3.5 4.5
3.5 4 5and
tion
atien
tryn and
lculat
try
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forward computation and still demonstrate agreement be-
tween the primary and MU verification methodology. Addi-
tionally, although it is desirable to use a single point within
the patient for comparison in all fields, this may not be fea-
sible in many circumstances, as a selected point in the patient
may be shielded from some beams. In such situations, sepa-
rate points may be required for different fields.
The dosimetry in regions of electronic disequilibrium car-
ries additional uncertainties and should be avoided during
point placement. This implies that point placement in regions
containing a high dose gradient should be avoided; as well, a
calculation point should not be placed near a field edge. Con-
servatively, points within 2 cm of a field edge may experi-
ence disequilibrium effects arising from lack of lateral scat-
ter. Patient geometry may also give rise to regions of
electronic disequilibrium when calculations incorporate cor-
rections for heterogeneous tissue densities.20,21 Since regions
of electronic disequilibrium are found near tissue interfaces,
calculation points should be located, if possible, in soft tissue
and positioned at least 1.0 cm downstream and 1.0 cm lateral
to tissue heterogeneous media interfaces to avoid large dis-
equilibrium effects. The ray-line path from the source to the
calculation point should provide a representative sample of
the bulk properties experienced by the treatment field; non-
representative ray-line paths such as paths through small het-
erogeneities like the trachea or passing tangentially through
the edge of a long bone disproportionately accentuate the
average density change along the path length and should be
avoided.
V.B. Differences in primary verification
and calculation methods
The primary MU calculation is typically based on a de-
tailed model of the fields and patient geometry. The primary
calculation from a modern 3D TPS accurately accounts for
patient scatter effects arising from blocked fields, scatter
changes arising from contour effects, and patient heterogene-
ity effects. The verification MU calculation in general will
not have as detailed a field or patient model as the primary
MU calculation and, consequently, will give rise to the ne-
cessity for an acceptance range between these two calcula-
tions. The factors that are likely to introduce the greatest
uncertainty in the verification calculation are blocked field
scatter, patient contour, and patient heterogeneity effects.
Historically, many verification calculations did not take
into account the effects of contour and heterogeneity, or used
planning system derived values for these corrections. For the
purposes of this discussion, this type of calculation is re-
ferred to here as a “uniform cube phantom” geometry. In
other cases, an approximate model of patient geometry was
applied in the form of simple correction factors such as a
scatter correction for tangentially incident fields or path
length type heterogeneity corrections; such calculations are
referred to as “approximate patient” geometry. If both the
primary MU and the validation calculation methods use the
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MU setting, then no additional uncertainties should arise. An
example of such a situation is the use of a manual look-up
table calculation for both the primary and the MUV calcula-
tions; another example is when both the primary and the
verification calculations use programs that have implemented
a Clarkson type calculation in the uniform cube phantom
geometry. Both situations will be referred to in this discus-
sion as having the “same patient geometry.”
V.C. Manual verification methods
Manual calculational methods using dosimetry look-up
tables are very mature and provide the basis for most MUV
calculations, either through a manual process or as input into
computer programs. All radiation therapy clinics should
maintain an accurate set of dosimetry tables, under the direc-
tion of a qualified medical physicist, which characterize the
external therapy beams used for the patient treatments. This
characterization should include, but is not limited to, the ref-
erence dose rate, output ratios, accessory attenuation factors,
off-axis ratios, and depth dependence. A number of dosimet-
ric systems for both photon and electron beams have been
detailed;22–25 however, physicists are encouraged to adopt the
format and terminology recommended by AAPM Task
Group 71 when their report becomes publicly available. An
example calculation system that can be used for MUV is
presented in Appendix A and is applied to clinically relevant
examples in Appendix B. The equation notation presented in
these appendices adheres as closely as possible to the draft
recommendations of TG-71. A summary description of this
notation is included in Table IV for reference. As with
computer-based MUV systems, discussed below, a periodic
review of dosimetric data in circulation for performing cal-
culations should be undertaken to ensure the appropriateness
and self-consistency of the data in use.
V.D. Computer-based MU verification programs
Most computer-based MU verification programs use an
automated table look-up method similar to that outlined in
Appendix A. Some more complex MU calculation programs
use pencil beam or convolution/superposition algorithms
based on the empirical data. For MU verification programs
that use a series of piecewise equations for a depth dose
curve, the MU calculation should be checked during com-
missioning at multiple points that fall within each piece of
the parametrization. These computer programs require peri-
odic QA to verify the continued data integrity and calculation
algorithm functionality.
V.E. Verification TPS
Some institutions may use a second independent planning
system for verification calculations. In this situation, identi-
cal beams and MU settings as in the primary plan should be
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Equation symbol Calculation type Parameter description
CF Photon, electron, arc
A dosimetric correction factor accounting for patient geometry effects.
Most commonly used to characterize tissue inhomogeneity corrections,
but can also include missing tissue and beam obliquity effects.
d Photon, electron
Physical depth of the point of calculation, defined as the projection
onto the central axis of the ray-line distance through the patient surface
to the point of calculation.
deff Photon, electron
Radiological depth to the point of calculation, scaled by the ratio of the
physical density of the medium to water along the ray-line path length.
dm Photon, electron The depth of maximum dose on the central axis.
d0 Photon, electron
Normalization depth for the dosimetric system; the depth at which
depth sensitive parameters take on a value of 1 or 100%. For electron
fields, d0 is set to dm.
Dm Photon, electron, arc
The depth of the maximum dose observed in a photon or electron depth
dose curve.
D Photon, electron, arc The dose to be delivered to the point at a depth of d.
D0 Photon, electron, arc
The dose rate at the normalization depth of d0 for the reference field
size r0. Typically set to 1 cGy/MU.
Fairr ,SSD Electron
The air-gap correction factor that parametrizes the deviation from pure
inverse square law behavior for an electron field.
g Electron
The measured distance or gap between the patient surface in the center
of the field and the standard treatment distance for an electron
applicator.
ILRx Arc
The percentage isodose line corresponding to the prescribed dose TDRx
in the distribution.
MU Photon, electron, arc
The counter setting for a treatment unit used to deliver the prescription
dose. May refer to time for external beam treatment units using
radioactive materials.
N Arc The number of arcs used in an arc plan.
OARd ,x Photon
The off-axis ratio, defined as the ratio of the dose at a depth d for a
point displaced by a distance x from the central beam axis measured at
the isocenter plane, to the dose on the central axis for the same depth,
machine output and scattering conditions.
PDDd ,r ,SSD Photon, electron
The percentage depth dose, defined as the ratio of the dose at depth d
to the dose at dm in water for a field size r and source to surface
distance of SSD.
PDDNd ,r ,SSD Photon, electron
The normalized percentage depth dose, defined as the ratio of the dose
at depth d to the dose at d0 in water for a field size r and source to
surface distance of SSD.
r Photon, electron The field size measured at the surface of the patient.
rc Photon, electron, arc
The field size in the plane of the isocenter defined by the variable
aperture collimation system closest to the radiation source. Typically
defined by the secondary jaws or MLC system replacing the secondary
jaws.
rd Photon, arc
The equivalent square of the treatment aperture defined by all
collimating devices projected to the plane normal to the central axis
containing the point of calculation at a depth d.
r0 Photon, electron, arc
The reference field size for the treatment modality that defines the
reference dose rate D0.Medical Physics, Vol. 38, No. 1, January 2011
514 Stern et al.: TG114 report 514used in the verification plan and the patient geometry used in
the verification should be derived from the same patient im-
age source as the primary calculation. A comparison point
common to both systems should be selected according to the
criteria discussed in Sec. V A and used to determine the level
TABLE IV.
Equation symbol Calculation type
Scrc Photon, arc
Sera ,r Electron
Sprd Photon, arc
SPD Photon
SSD0 Photon, electron, arc
SSD Photon, electron
SSDeff Electron
TF Photon, arc
TDRx Arc
TPRd ,rd Photon
TPRd¯ ,rd Arc
WFd ,r ,x Photon
WOARd ,x Photon
x Photonof dosimetric agreement between the two systems.
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Measurement confirmation of the dose delivered to a
point can be used as a verification method; however, mea-
surement has several drawbacks as a routine verification tool
ntinued.
Parameter description
The in-air output ratio for a field size rc to the normalization field size
r0, typically defined by the positional collimating system closest to the
radiation source.
The relative in-phantom dose for a field size r, within an applicator of
size ra, at a depth of d0 typically close to dm, normalized to the dose
for the reference field r0 within the reference applicator at the standard
treatment SSD.
The ratio of the total dose in phantom at the center of the field for a
field size of rd to the total dose for the reference field size r0 at a depth
of d0, for the same central axis energy fluence in both cases.
The source to point distance, defined as the projection of the ray-line
from the source to the point of calculation onto the beam central axis.
The source to phantom surface distance for the normalization condi-
tions and reference dose rate.
The source to phantom or patient surface distance for the point of cal-
culation, defined as the normal distance from the source to the plane
orthogonal to the central axis that contains the surface intersection
point of the ray-line from the source to the calculation point.
The effective dosimetric position of the electron source for which the
inverse square law behavior holds over the range of clinical useful dis-
placements from SSD0.
The attenuating tray factor for a photon beam, defined as the ratio of
the radiation field output with the tray in place to that of the open field
of the same field size and quality.
The prescribed daily tumor dose.
The tissue phantom ratio for an aperture defined equivalent square field
size rd at a depth of d.
The average TPR for an arced photon field size of rd, calculated from
an average of TPRs for the depths sampled at intervals along the full
arc path.
The attenuation wedge factor for a depth d and exposed field size in
the isocenter plane of r at an off-axis point x. Typically, the small re-
duction in field size resulting for tertiary shielding MLC, cerrobend
shielding can be neglected so that r=rc. In older dosimetry systems,
this factor has been presented as a composite of central axis and off-
axis factors; i.e., WFd ,r ,xWFd ,r ,0 ·WOARd ,x
The wedged off-axis ratio, defined as the ratio of the dose at a depth d
for a point displaced from the central axis by a radial distance x mea-
sured in the isocenter plane to the dose at the same point off-axis in an
open field of the same dimensions which delivers the same central axis
dose as the wedged field. Obsolete factor. See WF.
The off-axis distance, defined as the distance from the central axis to a
fan line through the point of calculation, measured in the isocenter
plane.Cofor nonmodulated fields. First, it can be difficult to ad-
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flat surfaces or fields with flash. Geometrical replication be-
comes even more difficult when heterogeneities need to be
taken into account. Second, measurements are time-
consuming. For the simple geometrical conditions that mea-
surements usually use, it is easier and faster to perform a
calculation, and under these conditions, the accuracy of a
basic manual calculation should be comparable to the mea-
surement accuracy.
Measurement is most useful when the difference between
the primary and the verification calculations is outside the
action levels. In this case, measurement can be used to help
determine the cause of the disagreement. Section VI B fur-
ther discusses this use of measurement. In addition, in vivo
verification measurement on the first day of treatment is rec-
ommended for specialized treatment procedures, such as to-
tal body irradiation and total skin electron treatment, which
are typically not planned with TPS but rather use a simple
hand or computerized calculation to determine MU.
V.G. Stereotactic therapy
Stereotactic radiosurgery and radiotherapy SRS and
SRT are highly conformal small target volume techniques
that are realized through a diversity of technical solutions
ranging from arced fields on a conventional linear accelerator
to specialized treatment units such as CyberKnife and Gam-
maKnife. The technique selected for performing a MUV will
depend heavily on the technical details of the radiation de-
livery process. The corresponding action levels need to take
into account any limitations of the MUV method, including
difficulties associated with small field dosimetry and the do-
simetric requirements of the particular treatment. For Gam-
maKnife and CyberKnife, the AAPM has two active task
groups that specifically address these specialized treatment
units TG 178 on Gamma Stereotactic Radiosurgery Dosim-
etry and Quality Assurance and TG 135 on QA for Robotic
Radiosurgery, and the reader is referred to these reports
when they become publicly available.
For linac-based SRS/SRT treatments using uniform arcs
or multiple uniform fields on a target large enough to estab-
lish electron equilibrium at the calculation point, the verifi-
cation techniques and action levels in this report can be ap-
plied. For smaller fields, the user should have available
measured data, e.g., from commissioning, that can be used in
the verification. The reports of TG 155 on Small Fields and
Non-equilibrium Condition Photon Beam Dosimetry, when
they become publicly available, and TG 101 on Stereotactic
Body Radiotherapy26 will provide useful references.
VI. ACTION LEVELS AND REMEDIAL ACTIONS
VI.A. Action levels for MU disagreement
Total uncertainty in absolute delivered dose of no more
than 5% is a widely accepted goal for effective radiation
treatments.1,3,27 One purpose of the independent MU verifi-
cation process is to help assure that this goal is achieved for
at least one representative point within the target volume.
Medical Physics, Vol. 38, No. 1, January 2011While AAPM Task Group 53 Ref. 5 and others28 gave rec-
ommended criteria for the absolute accuracy of the dose cal-
culation, the literature on the expected level of agreement
between primary and verification calculations for modern
image-based 3D planning systems is limited.29–34 The action
level guidelines given in Tables II and III are therefore based
primarily on the collective experience and expectations of
the task group members. A base action level of 2% was pos-
tulated for simple field geometries, consistent with the
TG-53 criterion of 2% dose accuracy between calculations
and measurements. From this starting point, additional range
was added to the level to account for the increased uncertain-
ties of complex treatment geometries that deviate from a uni-
form irradiation of the central region of a rectangular field
incident on a flat-surfaced homogeneous volume.
These guidelines are consistent with and inclusive of the
published studies of verification calculation agreement. Task
Group 40 Ref. 1 recommended agreement within 2% in
many circumstances, but indicated that 5% is more realistic
if sophisticated algorithms are used with substantial field
blocking or significant heterogeneity correction, or if elec-
tron beams are used. Leszczynski and Dunscombe29 used a
spreadsheet program that employed radiological path length
density corrections to verify calculations from a commercial
3D TPS. For all eight sites analyzed, the average ratio of
verification MU to TPS MU was 1.002, with standard devia-
tion of 0.012. The largest variations were seen for supraclav-
icular fields average=1.013, =0.010 and rectal fields
average=0.990, =0.009. However, they did not include
an off-axis factor for the supraclavicular fields nor did the
spreadsheet calculation account for beam hardening due to
the physical wedge for the rectal fields. Chan et al.30 com-
pared manual calculations to homogeneous calculations from
a 3D TPS with the aim of evaluating the usefulness of the
manual calculation as a verification tool. They found average
ratios of verification to TPS MUs for four sites ranged be-
tween 1.010 and 1.013, and standard deviations of 0.005–
0.016, with the largest variations encountered for breast
treatments and supraclavicular fields. They analyzed the su-
praclavicular fields by systematically reducing the calcula-
tion complexity removing wedges, flattening out the sur-
face, etc. and found increasing agreement with decreasing
complexity. They concluded that the largest single factor in-
fluencing the agreement between their verification and TPS
calculations was surface/contour irregularity, but there are
other contributing factors as well. Prado et al.,31 Ayyangar,32
Kay and Dunscombe,33 and Kay and Meyer34 all proposed
correction methods to better account for surface shape and
scattering characteristics in hand calculations for breast tan-
gents. With their corrections, they quoted 0.1%–2.3% aver-
age differences between verification and 3D TPS calcula-
tions.
Guidelines for action levels for disagreement between pri-
mary and verification MU calculations are given in Tables II
and III in terms of percentage differences. For low dose, low
MU fields, it may be more reasonable to use an absolute
difference criterion of 1–3 MU or 1–3 cGy for dose com-
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can result in a large percentage difference but negligible
clinical consequences. The action levels provided are only
guidelines and are not to be used as goals or requirements
for any particular situation. The particulars of the dose cal-
culation and verification methodology at each institution, as
well as particular patient circumstances, may affect these ex-
pectations. The radiation oncology physicist at each institu-
tion should evaluate the expectations for each circum-
stance to determine relevant criteria for verification MU
agreement for that institution. Different criteria may be
used for different treatment sites or techniques. The physicist
should also consider the clinical significance of each field to
the overall treatment.
The action level guidelines are divided into two tables,
depending on whether or not tissue heterogeneities are taken
into account in the primary calculation. Table II applies when
the patient density is assumed to be homogeneous, while
Table III applies when heterogeneity calculations are per-
formed. The task group strongly recommends that if the pri-
mary calculation applies heterogeneity corrections, then the
verification calculation should also, although the methods for
heterogeneity correction may, and typically do, differ. Fur-
ther discussion of heterogeneity-corrected calculations can
be found in Appendix A 1 a.
In order to obtain a valid verification calculation, the limi-
tations of both primary and verification calculation algo-
rithms must be recognized in the selection of the point of
comparison. The action level tables assume that either the
guidelines discussed in Sec. V A have been followed or cor-
rections are applied to account for disequilibrium effects.
These action level guidelines apply for conventional elec-
tron beam as well as all non-intensity modulated photon
beam calculations, including arcs and stereotactic fields. In
each case, the physicist should evaluate the complexity of
the field and calculation and determine the appropriate value
to use based on the table entries.
Appropriate care should be exercised in applying these
guidelines to the field-in-field FIF treatment beams. The
FIF technique incorporates into a single field a limited num-
ber of subfields that are usually forward-planned rather than
derived from computerized optimization. Some institutions
consider FIF a non-IMRT technique, while others classify it
as IMRT. The MU verification for these types of fields
should be performed accordingly. For those institutions veri-
fying these fields through calculations, it needs to be recog-
nized that it may be difficult to define a single verification
point that is adequate for all the subfields. Each center will
need to determine an acceptable minimum subfield sampling
for the calculation point and under what conditions a second
calculation point may be considered.
Explanation of table format. A number of factors will af-
fect the achievable agreement range between primary and
verification calculations for typical treatments at each insti-
tution. In general, algorithms applying the same methodol-
ogy would be expected to achieve a closer level of agree-
ment, while disparate algorithms e.g., pencil beam vs
convolution, or convolution vs Monte Carlo would be ex-
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reflected in the tables by the division of the columns into
these two broad categories. The manner in which patient
geometry information is used by the respective calculations
influences action levels as well. The more similarity that ex-
ists in the handling of patient geometry, the closer the level
of agreement expected. If both calculations use the same
patient model, whether it is a full CT data set or a uniform
cube phantom approximation, then a better agreement is ex-
pected than when one calculation uses the full CT data set
and the other uses a uniform cube phantom approximation.
An intermediate patient model between these two extremes
is also listed in the tables, referred to as “approximated pa-
tient geometry,” and is intended for calculations that apply
corrections to a uniform cube phantom geometry. Correc-
tions for such conditions as tangentially incident fields, het-
erogeneity calculations, or irregular surfaces would apply to
this category of patient geometry modeling. For
heterogeneity-corrected calculations, the uniform cube phan-
tom approximation is no longer sufficient to achieve an ac-
ceptable confidence level for MU verification, so that column
has been removed from Table III.
Field complexity also influences expected agreement be-
tween primary and verification calculations and is reflected
in the rows of Tables II and III, which are arranged roughly
in terms of increasing field complexity. “Contour change”
indicates situations with an oblique entrance or tangential
beam geometry, as well as surface irregularity. The examples
in Appendix B, which are summarized in Table V, illustrate
the application of these guidelines to a variety of clinical
cases.
VI.B. Remediation of MU discrepancies
Verification calculations that results in a variance from the
primary MU calculation outside the expected range for the
conditions of the calculation see Sec. VI A need to be in-
vestigated to ensure that the primary calculation has been
carried out to an acceptable accuracy. Thus, when a discrep-
ancy is noted, the first action of the physicist reviewing the
calculation should be to verify that a calculation error has not
been made see Sec. II B and Table I for a list of common
errors.
The investigation into a discrepancy should start with the
review and comparison of parameters used in the two calcu-
lations. This review should be sufficiently thorough to con-
firm that the correct parameters, such as energy, field size
and depth, were used, and that all accessories have been
properly taken into account. Particular attention should be
devoted to ensuring that both calculations correctly interpret
the treatment prescription in a consistent manner. The mag-
nitude of the discrepancy should serve as an indicator of the
cause; a very large difference would likely result from an
improper accounting of an attenuator such as a wedge, while
moderate differences could result from improperly account-
ing for the effects of block trays or bolus applied to the
patient. A large difference could also indicate a misinterpre-
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Medical Physics, Vol. 38, No. 1, January 2011tation of the prescribed dose or a misuse of the inverse
square law ISL. This minimal investigation typically occurs
during plan review as part of the routine planning QA, but
such inputs to the MUV should be carefully scrutinized for
accuracy and physical soundness in the context of the patient
geometry when the MUV is first generated.
If this basic review fails to identify the cause of an action-
able discrepancy, the next step should be to confirm that an
appropriate comparison point has been chosen. The guide-
lines for comparison point placement presented in Sec. V A
should be followed where possible. In situations where point
placement has been identified as an issue, new calculations
for a more appropriately positioned point should be per-
formed.
Differences in accounting for patient geometry between
the primary and the verification calculations can also lead to
large discrepancies between results. For example, the uni-
form cube phantom approximation used in many verification
calculations tends to overestimate the contribution of scatter
to the point of calculation in situations such as tangential
opposed beams for breast treatment. Methods such as de-
scribed in Appendix A 1 b and illustrated in the examples in
Appendix B should be applied to the verification calculation
to better estimate the scatter contribution.
Density corrections are required for verification of calcu-
lations which include heterogeneity effects see Appendix A
1 a. The verification calculation must at least take into ac-
count the radiological thickness of tissues overlying the point
of calculation. Point placement is crucial in obtaining agree-
ment within an acceptable range, and care must be taken that
the ray-line path from the source to the calculation point
provides a reasonable estimate of conditions experienced by
the calculation point. An example of where this would be
violated is a situation where the ray-line passes tangentially
through the cortex of a long bone and, consequently, overes-
timates the impact of the heterogeneity. Such conditions are
typically identified during planning review, but may not be
identified until the review of the verification calculation.
Heterogeneity calculations involving lung tissue tend to
be among the most difficult for achieving an acceptable veri-
fication calculation. A thorough understanding by the respon-
sible physicist of the capabilities and limitations of both the
primary and the verification MU calculations is required for
both setting the action levels at a clinic and for resolving
discrepancies between calculations under these conditions.
This knowledge will aid the physicist in determining to what
level radiation transport processes are modeled in the MUV
in comparison to the primary calculation, and how additional
corrections such as discussed in Appendix A 1 b and applied
in the examples of Appendices B 4–B 6 may be used to
confirm algorithmic differences as the source of observed
discrepancies. At a minimum, if a discrepancy is attributed to
differences in the calculation algorithms, an assessment to
confirm that the discrepancy is the correct order of magni-
tude and direction should be made. Small field calculations
within lung can be particularly difficult to achieve within the
desired accuracy since they experience effects from elec-
35A
BL
E
V.
Cl
in
ic
al
ex
am
pl
es
pr
es
en
te
d
in
A
pp
en
di
x
B
.
Ca
se
Ca
lc
ul
at
io
n
ge
om
et
ry
Sa
m
e/
di
ffe
re
nt
al
go
rit
hm
Pa
tie
nt
ge
om
et
ry
W
ith
in
ac
tio
n
le
ve
ls?
B
ra
in
H
om
og
en
eo
us
;m
in
im
al
sh
ap
in
g
D
iff
er
en
t
A
pp
ro
x,
pa
tie
nt
ge
om
et
ry
;fl
as
h
m
o
de
le
d
as
bl
oc
k
Ye
s
B
re
as
t
H
om
og
en
eo
us
;o
ff-
ax
is
w
ed
ge
D
iff
er
en
t
U
ni
fo
rm
cu
be
ph
an
to
m
N
o
A
pp
ro
x.
pa
tie
nt
ge
om
et
ry
;s
ca
tte
r
co
rr
ec
tio
n
fa
ct
or
Ye
s
A
pp
ro
x.
pa
tie
nt
ge
om
et
ry
;fl
as
h
m
o
de
le
d
as
bl
oc
k
Ye
s
M
an
tle
H
et
er
og
en
eo
us
;l
ar
ge
fie
ld
D
iff
er
en
t
A
pp
ro
x.
pa
tie
nt
ge
om
et
ry
;r
ad
io
lo
gi
ca
ld
ep
th
Ye
s
M
od
ifi
ed
m
an
tle
H
et
er
og
en
eo
us
;l
ar
ge
fie
ld
D
iff
er
en
t
A
pp
ro
x.
pa
tie
nt
ge
om
et
ry
;D
ay
’s
m
et
ho
d
N
o
A
pp
ro
x.
pa
tie
nt
ge
om
et
ry
;a
dd
iti
on
al
sc
at
te
r
co
rr
ec
tio
n
fa
ct
or
Ye
s
La
rg
e
fie
ld
lu
ng
H
et
er
og
en
eo
us
;l
ar
ge
fie
ld
D
iff
er
en
t
U
ni
fo
rm
cu
be
ph
an
to
m
h
om
og
en
eo
us

N
o
A
pp
ro
x.
pa
tie
nt
ge
om
et
ry
;r
ad
io
lo
gi
ca
ld
ep
th
Ye
s
Sm
al
lfi
el
d
lu
ng
H
et
er
og
en
eo
us
;s
m
al
lfi
el
d,
lo
w
-d
en
sit
y
he
te
ro
ge
ne
ity
D
iff
er
en
t
A
pp
ro
x.
pa
tie
nt
ge
om
et
ry
;r
ad
io
lo
gi
ca
ld
ep
th
N
o
A
pp
ro
x.
pa
tie
nt
ge
om
et
ry
;O
’C
on
no
r’s
th
eo
re
m
N
o
A
pp
ro
x.
pa
tie
nt
ge
om
et
ry
;e
ffe
ct
o
fc
al
cu
la
tio
n
po
in
tp
os
iti
on
Ye
s
El
ec
tro
n
di
str
ib
ut
io
n
H
om
og
en
eo
us
,m
in
im
al
fie
ld
sh
ap
in
g
D
iff
er
en
t
U
ni
fo
rm
cu
be
ph
an
to
m
Ye
stronic disequilibrium. In order to confirm that a discrep-
518 Stern et al.: TG114 report 518ancy between primary and verification calculations arises
from differences in the heterogeneity corrections and not
some other causes, a comparison between calculations both
using a homogeneous patient geometry may be performed to
confirm this cause. While such a calculation does not serve
to validate the treatment MU setting, it does serve to identify
the source of the discrepancy. A complete verification of the
MU setting in this situation would still require the derivation
and application of a correction factor CF applicable to the
patient geometry and perhaps a refinement of point position-
ing see the example in Appendix B 6 c.
The possibility of incorrect data or modeling in either the
primary or the verification dosimetry system cannot be dis-
missed. No matter how thorough the commissioning or QA,
it is not possible to completely verify a calculation system
under every possible situation. In addition, data in TPSs can
become corrupted, either through system failure or human
error. Parameters used for the calculation should be checked
against data tables for consistency with standard data and
reasonable data trends.
It is recognized that in some instances, even additional
correction methods may not be able to produce a verification
calculation within the expected level of agreement. In this
situation, it may be necessary to resort to a phantom mea-
surement to provide a verification of the treatment MU set-
ting. In geometries with complex surface shape or heteroge-
neities, an accurate measurement may not be practical or
even possible. In this situation, TPS commissioning tests per-
formed by the institution or reported in literature may be
useful to quantify the expected effects and provide guidance
on the direction and magnitude of the observed discrepancy.
When performing measurements to validate a calculation, it
is also important to consider and investigate treatment unit
issues as a possible source of discrepancy.
In situations where the same geometry is encountered in
multiple patients, technique-based corrections factors, de-
rived either from the literature see example in Appendix B
2 or from measurements, may be employed; however, dis-
agreements outside the action levels can result from condi-
tions, which deviate from the reference conditions, and such
a situation may need to be investigated through physical
measurements. Measurement, however, is often not the entire
solution since discrepancies may result from complexity in
the patient geometry, which may not be reproduced by the
measurement geometry.
Inevitably, there will be circumstances under which all
methods of calculation and measurement fail to achieve an
acceptable level of agreement between the primary treatment
and verification calculations. Such behavior may indicate
that the chosen method of treatment results in a large dosi-
metric uncertainty for the treatment in question and, conse-
quently, another technique or treatment approach might be
considered. In situations where it is judged that the planned
treatment must be delivered, then the physicist should inform
the oncologist that the planned treatment has a larger than
normal dosimetric uncertainty and should also report the
most likely cause of the uncertainty. This uncertainty does
not necessarily infer an error in treatment delivery; the dis-
Medical Physics, Vol. 38, No. 1, January 2011crepancy between primary and verification calculation re-
sults in many cases may not be due to inaccuracies in the
primary calculation but to limitations of the verification sys-
tem. When large unresolved discrepancies are routinely en-
countered for a particular type of treatment, then a detailed
investigation should be performed to clearly identify the
cause of the discrepancy and derive correction factors to ac-
curately account for the effect.
The resolution of discrepancies between the primary MU
and verification MU calculations requires an accurate de-
scription of the radiation environment in the patient at the
point of calculation. This information typically is provided
by the standard plan documentation generated by the TPS. It
is imperative that this information be provided in a format
that permits a physicist to identify the type and magnitude of
the individual corrections applied in the dose calculation and
to assess the appropriateness of these factors for the known
geometry of the patient. Ideally, this information should be
provided in the form of standard parameters that can be used
in a simple hand calculation, such as SSD, depth, radiologi-
cal depth, off-axis distance, and equivalent square. The task
group strongly recommends that commercial TPS vendors
make this information readily available in their plan sum-
mary documentation. Where such treatment parameters are
provided, it is also important that user documentation explic-
itly states the distance at which these parameters are defined
i.e., SSD, SAD, or point of calculation. An assessment of
the TPS plan summary documentation for these parameters is
an important consideration in the selection of a TPS for clini-
cal use.
VII. SUMMARY
The MUV is the independent verification overseen by a
qualified medical physicist that validates that the appropriate
machine settings are used to deliver the intended dose within
the patient. The MUV remains an important element of the
radiation therapy QA program that ensures a safe and accu-
rate patient treatment.4,11,12,36 It is usually performed as part
of the pretreatment plan check, and while it is an important
component of that check, it should be recognized that it is
only one component and does not alone constitute nor take
the place of a comprehensive review of the plan. In addition,
continuing education programs for all staff involved in treat-
ment planning and delivery, including physicians, therapists,
dosimetrists, and physicists, should include training to ex-
plain the MUV calculation and the adopted institution action
levels under various treatment conditions.
A key aspect of the MUV that ensures its continued value
as a QA tool is the independent nature of the check. Despite
the increase in treatment complexity that causes a reliance on
the primary TPS for the determination of some of the treat-
ment parameters, the verification can and should be indepen-
dent in several key aspects. First, a calculation program
and/or methodology that is separate from that of the primary
calculation should be used. Second, the beam data and treat-
ment parameter files should be separate and independent of
those used by the primary TPS. Finally, when the electronic
519 Stern et al.: TG114 report 519transfer of patient specific parameters from the primary to
the verification system is used, the physicist should assess
and evaluate the suitability of those parameters by an inde-
pendent means, which, for example, may include simple es-
timation of an aperture equivalent square from a BEV, or
comparison of physical and radiological depths to ranges
typical of the anatomical site based on clinical experience.
The establishment and maintenance of an independent MUV
program is an important responsibility of the medical physi-
cist.
A variety of methods can be used to perform the MUV, as
described in Sec. V and Appendix A. All software programs
used for the verification calculation should be thoroughly
commissioned and tested prior to use, as should the primary
TPS. It is important that the physicist knows the accuracy
and limitations of both the primary and the verification sys-
tems in order to set reasonable and achievable action levels
and to better interpret the causes of differences between the
two results.
The level of agreement achievable between primary and
verification calculations depends on the details of the patient
geometry, the primary and the verification calculation pro-
grams, and the clinical situation, in addition to whether cor-
rections for tissue heterogeneities are used. It is therefore
reasonable and expected to have different action levels for
different situations. Each institution must determine the
proper action levels for that particular clinic. Results from
planning system commissioning are useful in establishing
these levels. Tables II and III may be used as guidelines, but
should not be adopted without evaluation. The action levels
established by the institution should be documented in writ-
ten protocols and disseminated to staff through appropriate
continuing education activities. With appropriate action lev-
els and responses, the MU verification is both an effective
and efficient QA tool that can help identify and reduce treat-
ment errors.
APPENDIX A: MANUAL CALCULATION
METHODOLOGIES
1. Manual photon calculations
The basis of any MU calculation system used for the veri-
fication of the delivered dose is the derivation of a dose or
dose rate delivered in patient from the known dose rate un-
der the reference conditions. A typical methodology for per-
forming this calculation for a simple water equivalent slab
phantom geometry is illustrated in Fig. 1 using a conven-
tional manual calculation system.22,24,37 Dose to point P is a
product of the reference dose rate, number of MU used, in-
air output ratio Sc, phantom scatter factor Sp, the TPR,
and the distance correction factor. As shown schematically in
Fig. 1, the dose to a point P in a flat-surfaced water phantom
can be calculated using the equation,Medical Physics, Vol. 38, No. 1, January 2011D = MU · D0 · Scrc · Sprd · TPRd,rd
· SSD0 + d0SPD 
2
· OARd,x · TF · WFd,r,x . A1
The parameters used in this and other equations follow the
draft recommendations of AAPM Task Group 71 and are
defined in Table IV. TPSs do not always use these defini-
tions, particularly for off-axis ratio OAR distance and
depth; users must understand how parameters are defined
within their TPS.
As shown in Fig. 1, the product of MUs and the normal-
ization dose rate dose rate at the normalization point for the
reference field will yield the dose at the normalization point
for the reference field size. However, calculation conditions
are typically different from the reference conditions. The
next three terms correct for the changes in output, attenua-
tion, and scatter conditions from the reference conditions.
The in-air output ratio, Sc, also called the collimator scatter
factor, corrects for treatment unit output changes with field
size. It is typically a complex function of the field size pro-
jected to the isocenter and depends on the design of the treat-
ment unit collimation system.38–41 The phantom scatter fac-
tor, Sp, and the TPR together correct for differences from the
reference conditions in scatter and attenuation, with Sp pri-
marily accounting for changes in scatter and TPR accounting
for the effects of tissue attenuation as well as changes in
scattering conditions with depth. These factors depend on the
effective equivalent square42–44 of the irradiated area at
SPD, which is typically estimated from the field shape de-
fined by the MLC or poured blocks. The ISL term accounts
for the intensity change resulting from source-to-point dis-
tance differences between the calculation and reference po-
sitions. The OAR also accounts for changes in intensity, but
FIG. 1. Development of Eqs. A2 and A3 for photon dose calculation to a
point in a water equivalent slab phantom. Successive application of factors
transforms the dose rate from the reference condition to the conditions of
treatment geometry and depth. Steps in the calculation where the phantom
scatter differs from the irradiating field size during the application of Sc and
ISL factors are indicated by sectioning the phantom, where the portion en-
closed by the solid lines signifies the inclusion of reference field size phan-
tom scatter. The solid circle represents the position of the calculation point,
while the dashed line crossing several phantoms indicates changes in the
point distance from the source.in this case resulting from changes in beam characteristics
520 Stern et al.: TG114 report 520away from the central axis. As these changes include both
beam quality and intensity, this factor is a function of off-
axis distance and depth.
The factors TF and WF account for the attenuation from
beam modulators, shaping devices, and patient support de-
vices in the beam path required for typical treatment plans.
Thin plastic trays placed into the treatment beam to support
field-shaping blocks typically reduce the beam intensity by a
few percent and are frequently characterized by a single fac-
tor, TF, depending only on beam energy for all points in the
field. The behavior of the wedge factor, WF, on treatment
settings is closely tied to the design of the treatment unit,
The inhomogeneity CF is defined as
Medical Physics, Vol. 38, No. 1, January 2011particularly the position of the wedge relative to the second-
ary and tertiary collimation system.45–48 This factor primarily
accounts for the changes in intensity arising along a ray-line
path to the point of calculation due to either the thickness of
material or the change in the jaw position during irradiation
in the case of a virtual wedge, and as such exhibits large
variations with off-axis position x. The WF typically ac-
counts for field size, depth, and SSD dependent effects49–51
arising from scatter radiation emanating from the wedge fil-
ter itself.
Monitor unit calculations for isocentric beams can be per-
formed by rearranging Eq. A1 into the form,MU =
D
D0 · Scrc · Sprd · TPRd,rd · OARd,x · TF · WFd,r,x · CF
·  SPDSSD0 + d0
2
. A2
Additional corrections for specific patient geometry may be incorporated through the CF factor to account for missing tissue
in tangential geometries, sloping surfaces, and tissue heterogeneities.
Monitor unit calculations for nonisocentric en face beams can also be done using the percent depth dose values according
to Eq. A3,
MU =
D · 100%
D0 · Scrc · Sprd0 · PDDNd,rd0,SSD · OARd,x · TF · WFd,r,x · CF
·  SSD + d0SSD0 + d0
2
, A3where the TPR term in Eq. A2 has been replaced by a
percentage depth dose term appropriate to the exposed field.
This also affects the ISL term compared to Eq. A2, which
now accounts only for that part of the change in intensity due
to a difference between the calibration and treatment SSDs.
a. Heterogeneity corrections
The heterogeneity correction is usually small in most
clinical sites, such as breast or prostate, but can be substan-
tial for chest treatments when a large volume of lung is being
irradiated or when the tumor is surrounded by lung tissue.
Typically, heterogeneity corrections will improve the dose
accuracy compared to a homogeneous dose calculation.
For a heterogeneous dose calculation, the most important
parameter is the radiological depth along the ray-line to the
point of calculation. While the radiological depth is typically
the largest component for this correction, in low-density re-
gions, such as the lung, electronic disequilibrium effects due
to the lateral extent of the field and rebuild-up can also be
significant.20,52 Care must be taken to avoid selecting a cal-
culation point near the tissue-lung interface to avoid these
effects due to secondary electron transport.CF =  dose in heterogeneous mediumdose at same point in homogeneous medium .
A4
The ratio of TAR RTAR method is based on the
radiological-path-length scaling theorem proposed by
O’Connor.53,54 According to this theorem, particles in a me-
dium of half the density will travel twice as far to undergo
the same number of interactions. Using more conventional
parameters, the RTAR inhomogeneity correction factor may
be calculated using the equation
CF = TPRdeff,rdTPRd,rd  , A5
where the peak scatter factor term divides out in the ratio,
leaving only a ratio of TPR terms. The RTAR method calcu-
lates the dose contribution from the primary beam accurately
but the scatter contribution is inaccurate because the size,
shape, and location of the heterogeneous medium are not
included in the scatter integration. RTAR assumes that the
heterogeneous medium is infinite in the lateral dimensions
infinite slab approximation. Batho55 proposed a method
that was later extended by Sontag and Cunningham,56 based
on the radiological path length scaling for the primary dose,
expressed as
521 Stern et al.: TG114 report 521CF =  TPRd3,rde3−e2TPRd2 + d3,rd1−e2 , A6
where distances d and electron densities  are defined in Fig.
2. These simple ratio methods described above do not take
into account the effect of the lateral dimension of the hetero-
geneity. To characterize the impact of the size of an inhomo-
geneity on scatter, an effective equivalent square can be
used.57 It is usually determined as the electron density scaled
lateral dimension, r. While the effective square can be cal-
culated through an equivalent TAR method for TPS calcula-
tions, it is rare for it to be used in MUV calculation. For
more information on these methods, refer to AAPM Report
No. 85 from Task Group 65.20
In addition to calculation methods, the quality of relative
electron density information in the planning CT needs to be
considered when employing heterogeneity corrections. Non-
tissue high-Z materials can be introduced into the patient
either through prosthetic materials implanted in the patient or
the use of CT contrast to help visualize target regions. For
patients with high-Z material implants such as hip prostheses
within the treatment field, the reader is referred to the AAPM
Task Group 63 report for guidance in properly accounting for
the dosimetric effects.58 The same techniques may also be
used for other materials that exhibit an anomalously high
density, such as dental amalgam and bone cement. The use of
radio-opaque contrast during CT simulation can also intro-
duce anomalously high-density regions into the planning CT,
which will not be present during treatment. While several
clinical investigations have found that such regions in the
vicinity of the target introduce only a small dose perturbation
into the calculation,59–64 instances where it is judged to have
a significant effect can be addressed by contouring the region
d1
d2
d3
e1=1
e2
e3
r
FIG. 2. Photon dose calculation to a point in a heterogeneous phantom. The
first layer of material is assumed to be water equivalent.and setting the relative electron density to that of the sur-
Medical Physics, Vol. 38, No. 1, January 2011FIG. 3. BEV showing field blocking used to estimate the exposed equivalent
field size for the brain field MUV in Appendix B 1. The calculation point
position in the field is indicated by the circle.FIG. 4. Geometry for standard breast MUV calculation in Appendix B 2. a
Placement of the calculation point within the patient in soft tissue and away
from the tissue interfaces. b BEV for the field used to estimate the missing
scatter from the tangential field. The dashed white line indicates the position
of the breast horizon and the crossed circle indicates the location of the
calculation point in the field.
522 Stern et al.: TG114 report 522rounding tissue.20 In these instances, the best estimate of
regional relative electron density should be used for both the
primary and the MUV calculations.
b. Scatter corrections
Corrections in MUV calculations are typically required to
account for changes in the scattered radiation from uniform
cube phantom geometry arising from patient and beam ge-
ometry effects. Correction methods of this type can typically
be expressed through a change in the field size,
CF = Sprd · TPRd,rdSprd · TPRd,rd , A7
where rd is the effective field size. A number of different
methodologies for calculating the effective field size have
been reported for specific geometries such as breast
tangents.31,33,34 Simpler methodologies using this approach
have also been used for tangential fields treating areas such
as larynx and limbs. For these corrections, an equivalent field
size is obtained by considering the area of missing tissue
seen in the BEV as though the region were under a shaped
block or by estimating an average exposed field width from
the observed BEV horizon. More complex scatter corrections
may be required for special circumstances such as arise when
field attenuators are used or in reduced scatter conditions
such as mediastinal treatments irradiating a significant por-
tion of lung. In these cases, a more careful assessment of the
scatter may be obtained using Day’s method65,66 to estimate
TABLE VI. Whole brain case.
Reference
conditions
Treatment
description
Dosimetric
parameters
SAD 100 cm D 75 cGy
rc equivalent
square 21.0 cm
SSD0 98.5 cm SPD 100 cm
rd equivalent
square 15 cm
d0 1.5 cm d 7.6 cm Scrc 1.033
r0 1010 cm2 rc 2220 cm2 Sprd 1.009
D0 1 cGy/MU x 12 cm TPRd ,rd 0.878
Blocked
field areaa 29% OARd ,x 1.042
aEstimated from BEV shown in Fig. 3.
TABLE VII. Wedged breast case.
Reference conditions Treatment description Unif
SAD 100 cm D 91.9 cGy rd equivalent
SSD0 98.5 cm d 6.0 cm Scrc
d0 1.5 cm rc 10.517 cm2 Sprd
r0 1010 cm2 rd 817 cm2 TPRd ,
D0 1 cGy/MU x 2.6 cm WFd ,r
Missing scatter 2 cm in field width OARdMedical Physics, Vol. 38, No. 1, January 2011the reduced scatter from lower density material. In most
clinical cases, the scatter correction in a photon field can
account for a 2%–8% change in the MU value, but can be
larger for small stereotactic fields.
c. Arc therapy
The formalism for an arc beam calculation differs subtly
from a static beam. The formula
MU =
D
D˙ 0 · SCrC · SprC · TPRd,rC
A8a
is very similar to the more generalized equation A2, with
the elimination of accessory factors, and the modification of
TPR. This formalism only supports a calculation to the iso-
center of the arc. In this calculation, the depth to the iso-
center is regularly sampled over the path of the arc and the
mean TPR is calculated according to the equation,
TPRd,rC =
1
n

i
n
TPRdi,rC , A8b
where the index i sums over the equally spaced segments
along the arc e.g., every 10°.24
The preceding formalism applies only to static arc deliv-
ery. A number of dynamic arc delivery techniques such as
conformal arc therapy, intensity modulated arc therapy, volu-
Dosimetric parameters
ube Averaged geometry Reduced scatter
re 10.9 cm rd equivalent square 10.9 cm rd equivalent square 8.9 cm
1.013 Scrc 1.013 Scrc 1.013
1.004 Sprd 1.004 Sprd 0.990
0.901 TPRd ,rd 0.901 TPRd ,rd 0.891
0.660 WFd ,r ,x 0.660 WFd ,r ,x 0.660
1.020 OARd ,x 1.020 OARd ,x 1.020
CF 0.96
FIG. 5. BEV of the anterior upper mantle field calculated in Appendix B 3.
The circle shows the prescription point used in the MUV calculation, which
has been located in the middle of the mediastinum, well away from low-
density tissue interfaces.orm c
squa
rd
,x
,x
523 Stern et al.: TG114 report 523metric modulated arc therapy, and helical IMRT tomo-
therapy have been developed and have been implemented in
a number of clinics. A consistent methodology for an inde-
pendent MUV calculation of these modalities has yet to be
developed.
2. Manual electron calculations
Electron beams are typically treated in en face geometry
with custom field-defining apertures. The output of the elec-
tron beam depends on the beam energy, the SSD, the
applicator/cone size, and the size of the field-defining aper-
ture. Typically, electron beam output factors are measured at
the depth of maximum dose for different field sizes and dif-
ferent SSDs. These measured values are used to compute the
monitor units.
For regularly shaped large field sizes at standard SSD, one
commonly used formula for the electron calculation is
MU =
D
D0 · Sera,r
. A9
The output factor, Se, for a rectangular field of WL can be
estimated using the following relationship:67
Sera,LW = 	Sera,L L · Sera,WW . A10
For nonstandard extended SSDs, there are two techniques
to correct for the change in distance, g, from the reference
conditions: The effective SSD method,
TABLE VIII. Mantle case.
Reference
conditions
Treatment
description
Dosimetric
parameters
SAD 100 cm D 84.6 cGy rd equivalent square 19.4 cm
SSD0 98.5 cm deff 8.7 cm Scrc 1.037
d0 1.5 cm rc 36.425 cm2 Sprd 1.028
r0 1010 cm2 x 1.8 cm TPRd ,rd 0.845
D0 1 cGy/MU SPD 98.4 cm OARd ,x 1.008
TF 0.960
TABLE IX. Modified mantle case.
Reference conditions Treatment description
SAD 100 cm D 59.9 cGy
SSD0 98.5 cm SPD 106.0 cm
d0 1.5 cm d 15.2 cm
r0 1010 cm2 deff 15.0 cm
D0 1 cGy/MU rc 2213 cm2
x 0.9 cm
Missing scatter lateral lung tissue
aCalculated using Day’s method. See text for details.
Medical Physics, Vol. 38, No. 1, January 2011MU =
D
D0 · Sera,r
· SSDeff + d0 + gSSDeff + d0 
2
, A11
and the air-gap parametrization method,
MU =
D
D0 · Sera,r · fairr,SSD
· SSD0 + d0 + gSSD0 + d0 
2
.
A12
While these methods work well for typical regularly shaped
fields, careful application is advised for irregular and small
fields to ensure that loss of electron scatter does not intro-
duce significant deviations in dose. In some cases, the output
factor may be measured directly at the treatment distance and
used directly in Eq. A9; if a mixture of correction methods
is employed, extreme care in the MU calculations should be
exercised to ensure the effect of the extended distance is not
applied twice. For more details on the formalism for dosim-
etric parameters and measurement techniques, refer to
AAPM Task Groups 25,68 70,69 and 71 report on MU calcu-
lations.
APPENDIX B: MONITOR UNIT VERIFICATION
EXAMPLES
The following examples of verification calculations sum-
marized in Table V were selected to illustrate the application
Dosimetric parameters
Field shaping Lung scatter
equivalent squarea 12.5 cm rd equivalent squarea 12.5 cm
Scrc 1.012 Scrc 1.012
rd ·TPRd ,rd a 0.668 SprdTPRd ,rd a 0.668
OARdeff ,x 1.001 OARdeff ,x 1.001
CFa 0.943
FIG. 6. BEV for the modified mantle field of Appendix B 4. The calculation
point centered in the mediastinum is marked by the circle.rd
Sp
524 Stern et al.: TG114 report 524of Tables II and III and the remedial correction methods that
could be applied in a range of different clinical situations.
For each case, the MU or the dose to a selected point is
compared to that from the primary TPS and the difference is
analyzed according to the action level criteria in Tables II
and III. All examples have been selected from actual clinical
treatments, with primary MU calculated by a TPS with pen-
cil beam or convolution-superposition algorithm using pa-
tient CT data. The data used in each MUV calculation are
listed in a separate table and are classified as to the reference
conditions used for the calculation, the description of the
calculation point extracted from the plan description, and the
associated dosimetric parameters used for the MUV calcula-
tion.
A variety of the methodologies discussed in Appendix A
are used for the MUV to illustrate the different approaches
that can be employed and the corresponding application of
Adopting a factor of CF=0.96 for standard breast treatment
Medical Physics, Vol. 38, No. 1, January 2011the criteria tables. Since some of these methods can be time-
consuming to perform on a routine basis, the task group en-
courages the user to adopt an appropriate balance of effort,
efficiency, and accuracy when implementing his/her MUV
program. While the manual calculation formalism is used in
these examples, the same approaches to resolving discrepan-
cies arising from commercial MUV software can also be
employed.
1. Whole brain case
The following example is a simple two-field whole brain
case. The left lateral 6 MV photon beam was calculated. For
this case, monitor units were calculated at a point in the
isocenter plane that is marked with a dot in Fig. 3. The field
flash was approximated as blocked field. The MUV calcula-
tion was determined from Eq. A2,MU =
D
D0 · Scrc · Sprd · TPRd,rdSSD0 + d0/SPD2 · OARd,x
, B1
where the factors for tray attenuation and wedge attenuation have been dropped as these accessories are not used.
The dosimetric parameters listed in Table VI yielded a MUV of 78.7 MU. The TPS calculated 79 MU. The agreement is
within 1% and falls within the 3% action level for homogeneous conditions using different calculation algorithms and
approximate patient geometry with minimal field shaping.
2. Wedged breast case
In the following tangent breast case, 6 MV photon beams were used, in conjunction with a 30° wedge. The treatment setting
of 159 MU was obtained from a homogeneous TPS calculation for the medial field. The MUV calculation for the medial field
was performed for a point positioned, as shown in Fig. 4a. Three different calculation approaches were used in this example
to deal with tangential beam flash and patient contour issues. Each of these approaches used the same equation, based on Eq.
A2,
MU =
D
Do · Scrc · Sprd · TPRd,rd · SSD0 + d0/SPD2 · OARd,x · WFd,r,x · CF
B2
for the plan parameters listed in Table VII.a. Uniform cube phantom calculation
Calculating the MUV for a uniform cube phantom in
which full scatter condition is assumed yields a MUV value
of 149.0, which is 6.3% less than the TPS value and be-
yond the action level of 5% difference for different algo-
rithms, uniform cube phantom approximation for an off-axis
wedge distribution. In this situation, a more accurate esti-
mate of patient geometry effects may be required to achieve
an acceptable MUV.
b. Technique averaged patient geometry
The effect of missing scatter and contour change for stan-
dard breast treatment geometries has been investigated by
several authors,31,33,34 with each finding that the dose is re-
duced by a constant factor over a large range of phenotypes.geometry from the literature31 and using this in Eq. B2,
together with the factors appropriate for the uniform cube
phantom approximations, yields a MUV value of 155 MU,
which is within 2.5% of the TPS calculated MU setting
and within the 4% action level for different algorithms, ap-
proximate patient geometry for an off-axis wedge distribu-
tion give in Table II.
c. Reduced field size scatter correction
The effect of missing tissue from tangential fields is esti-
mated by treating the horizon of the breast seen in Fig. 4b
as though it defines a block and so reduces the irradiated
volume of tissue. This yields a value of 152.8 MU, which is
within 3.9% of the 159 MU calculated by the TPS. This is
525 Stern et al.: TG114 report 525within the homogeneous action level for different algorithms,
approximate patient geometry, and off-axis wedged fields in
Table II.
3. Mantle case
The following example is a typical SAD mantle treatment
FIG. 7. BEV for AP lung treatment field described in Appendix B 5. The
circle indicates the MUV calculation point.using a 6 MV parallel-opposed pair. A heterogeneous TPS
Medical Physics, Vol. 38, No. 1, January 2011calculation for a point located in the AP field, as shown in
Fig. 5, yielded a beam setting of 97 MU. The blocked area is
defined by a mixture of MLC and poured blocks. The MU
was verified using the equation,
FIG. 8. Orthogonal views of MUV point within a small field lung lesion
calculated in Appendices Secs. B 6 a and B 6 b. The isocenter was selected
as the calculation point.MU =
D
Do · Scrc · Sprd · TPRd,rd · SSD0 + d0/SPD2 · OARd,x · TF
. B3
An independent Clarkson integration of the missing scatter, including blocks and tangential flash, gave an equivalent square of
19.4 cm at the point. Using the parameters in Table VIII, the MU calculated for the AP mantle field is 94.0 MU, which is 3.2%
less than the TPS value of 97 MU. The agreement is within 3.5% and below the action level for different algorithm,
approximate patient geometry, and large field listing in Table III. The MUV calculation could be improved by using an
improved estimate of the blocked field scatter reduction which accounted for the near proximity of the lung field and would be
expected to further increase the number of MU in the MUV calculation.
4. Modified mantle case
This example demonstrates the use of Day’s method66 to determine the effects of field shaping and reduced lung scatter
when heterogeneity corrections are required. A modified mantle is treated with a parallel-opposed pair of 6 MV beams. The
MUV calculation is presented for the posterior field for the calculation point shown by the circle in Fig. 6. The MUV was
performed using the equation,
MU =
D
Do · Scrc · Sprd · TPRd,rd · SSD0 + d0/SPD2 · OARd,x · CF
, B4
with the parameters listed in Table IX.
a. Field shaping effects
Day’s method was used to estimate the effect of shielding-reduced scatter in the term Sprd ·TPRd ,rd according to the
equation,
526 Stern et al.: TG114 report 526Sprd · TPRd,rd =
1
2 Sp22.8 cm · TPR15 cm,22.8 cm − Sp10.9 cm · TPR15 cm,10.9 cm
+ Sp8.4 cm · TPR15 cm,8.4 cm B5
based on calculating half the scatter dose from the symmetric rectangle centered on the calculation point 2221 cm2 less
the central portion containing the narrowed shielding 227 cm2, with the last term accounting for the reduced shielding
area approximately centered on the calculation point 107 cm2. The equivalent square field sizes were projected to their
size at the SPD. Using the data from the clinic’s dosimetry tables yields a value for Sprd ·TPRd ,rd=0.668, corresponding
to an equivalent square of approximately 12.5 cm. Using these values in Eq. B4 generates a MUV value of 99.6 MU, which
is 5.3% below the primary MU calculation, and beyond the action level of 3.5% suggested in Table III for this type of
calculation.
b. Field shaping and lung scatter effects
A further correction factor to account for reduction in lateral scatter due to reduced tissue density is obtained by treating the
patient geometry as though the calculation point was embedded in unit density mediastinal tissue, surrounded laterally by
reduced density lung tissue. In this case, the mediastinal tissue is approximated as a BEV region with dimensions of 5
12.5 cm2, embedded in a 12.512.5 cm2 equivalent square region of lung tissue. Equation A7 then takes the form,
CF =
Sp7.1 cm · TPR15 cm,7.1 cm + rel · Sp12.5 cm · TPR15 cm,12.5 cm − Sp7.1 cm · TPR15 cm,7.1 cm
Sp12.5 cm · TPR15 cm,12.5 cm
=
rel · Sp12.5 cm · TPR15 cm,12.5 cm + 1 − rel · Sp7.1 cm · TPR15 cm,7.1 cm
Sp12.5 cm · TPR15 cm,12.5 cm
. B6
TABLE X. Large field lung case.
Reference conditions Treatment description
Dosimetric parameters
Homogeneous calc. Radiological depth
SAD 100 cm MU 54 MU 45.17 open, 8.83 wedged rd equivalent square 12.4 cm rd equivalent square 12.4 cm
SSD0 100 cm SPD 100 cm Scrc a 1.008 Scrc a 1.008
d0 1.5 cm rc 1716 cm2 Sprd 1.004 Sprd 1.004
r0 1010 cm2 d 11.8 cm TPRd ,rd 0.749 TPRdeff ,rd 0.859
D0 1 cGy/MU deff 7.7 cm OARd ,x 1.014 OARdeff ,x 1.015
x 3.0 cm WFd ,r ,0 0.266 WFdeff ,r ,0 0.260
Motorized 60° wedge 16.35% of MU WOARd ,x 0.987 WOARdeff ,x 0.987
aBased on MLC aperture equivalent square for a unit where the MLC replaces the upper jaw.
TABLE XI. Initial calculation point position in B6 small field lung case.
Reference conditions Treatment description
Dosimetric parameters
Blocked equivalent square O’Connor’s theorem
SAD 100 cm D 351.8 cGy rc equivalent square 3.5 cm rc equivalent square 3.5 cm
SSD0 100 cm SPD 100 cm rd equivalent square 3.5 cm rd equivalent squarea 1.1 cm
d0 1.6 cm d 13.8 cm Scrc 0.946 Scrc 0.946
r0 1010 cm2 deff 4.2 cm Sprd 0.971 Sprd 0.951
D0 1 cGy/MU x 0.0 cm TPRdeff ,rd 0.937 TPRdeff ,rd 0.927
OARdeff ,x 1.000 OARdeff ,x 1.000
aScaled according to O’Connor’s theorem. See text for details.
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527 Stern et al.: TG114 report 527Using a relative density rel=0.25 for lung and the clinical
values of Sp7.1 cm=0.990 and TPR15 cm,7.1 cm
=0.624 in Eq. B6, a value of CF=0.943 is obtained, and the
resultant MUV value of 105.6 MU falls within +0.6% of the
TPS derived value, well within the 3.5% action level of
Table III.
5. Large field lung case
In this example, the MUV takes the form of an indepen-
dent prediction of the dose to a point rather than a determi-
nation of MU. The target in the lung is treated using 6 MV
photon beams in a four-field technique. The calculation point
is 3 cm off-axis at SPD=SAD=100 cm blue circle in Fig.
7. The MUV calculation is provided for the AP beam, which
uses a 60° motorized wedge for 16.35% of the MU. The
primary MU calculation used a convolution-superposition al-
gorithm with heterogeneity corrections. The MUV calcula-
tion was done with and without heterogeneity corrections to
FIG. 9. Orthogonal views of alternate MUV calculation point placed within
the center of the normal density tissue within the target volume, discussed in
Appendix B 6 c. The selected point is placed away from tissue interfaces as
discussed in Sec. V A.
FIG. 10. BEV for a single direct electron field calculation of Appendix B7,
with the calculation point indicated by the circle.
Medical Physics, Vol. 38, No. 1, January 2011illustrate the need to use corrections in the verification when-
ever it is used in the primary calculation. Equation A1 is
used
D = MU · D0 · Scrc · Sprd · TPRd,rd
· SSD0 + d0/SPD2 · OARd,x · TF · WFd,r,x
B7
together with parameters listed in Table X.
a. Homogeneous calculation
Using the factors for a homogeneous dose calculation, a
dose of 37.6 cGy from the field is obtained, which differs
from the TPS calculated dose of 41.9 cGy by 10.3%, which
is beyond the 5% action level of Table II for different algo-
rithms, uniform cube phantom with wedge.
Radiological depth correction
Using the radiological depth reported by the TPS to derive
the dosimetric parameters yields a dose of 43.1 cGy, which
differs by 2.9% from the TPS predicted dose, and is within
the large field action level of 3.5% for approximate patient
geometry in Table III.
6. Small field lung case
The following example is a ten-field lung case using 6
MV photon beams. The RAO field, shown in Fig. 8, requires
443 MU as determined by a commercial TPS using a
convolution-superposition algorithm performing a heteroge-
neous calculation. Adapting Eq. A2 by dropping terms for
accessories not used in this treatment, the verification MU
was calculated according to
TABLE XII. Adjusted calculation point position in B6 small field lung case.
Reference
conditions
Treatment
description
Dosimetric
parameters
SAD 100 cm D 354.4 cGy rc equivalent square 3.5 cm
SSD0 100 cm SPD 100 cm rd equivalent square 1.1 cm
d0 1.6 cm d 13.8 cm Scrc 0.946
r0 1010 cm2 deff 4.6 cm Sprd 0.951
D0 1 cGy/MU x 0.4 cm TPRdeff ,rd 0.902
OARdeff ,x 1.001
TABLE XIII. Direct electron case.
Reference
conditions
Treatment
description
Dosimetric
parameters
SAD 100 cm Dd 300 cGy Sera ,6 cm6 cm 0.995
SSD0 100 cm SSD 105 cm Sera ,10 cm10 cm 1.005
d0 3.0 cm d 3.6 cm Sera ,6 cm10 cm a 1.000
r0 1010 cm2 PDD 97% g 5 cm
D0 1 cGy/MU ra 1010 cm2 SSDeff 86 cm
r 610 cm2
aCalculated from the square aperture Se values using Eq. A10.
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D
Do · Scrc · Sprd · TPRd,rd · SSD0 + d0/SPD2 · OAR
. B8In this case, two different methods were used to estimate the
reduction in scatter dose from field blocking and patient ge-
ometry. The use of a different calculation point to achieve
agreement within tolerance was employed in a third calcula-
tion.
a. Standard blocked equivalent square
The dosimetric effects of scattered radiation were charac-
terized only by the blocked field area with a radiological
depth used for density corrections. Using the values found in
Table XI in Eq. B8, the MUV calculation for the RAO field
was 396 MU, which is 12% less than the TPS calculated
value of 443 MU, and outside the action level in Table III for
different calculation methods and small fields with inhomo-
geneity corrections.
b. O’Connor’s theorem for blocked equivalent square
A more detailed treatment of the scattering conditions ex-
perienced by the calculation point within the patient was
obtained based on O’Connor’s theorem,52 which holds that
the equivalent square field characterizing the reduced scatter,
EqSqeff, can be approximated by the equation, EqSqeff
=EqSqblockeddeff /d. An equivalent square of 1.1 cm is ob-
tained, generating the parameters listed in Table XI under the
heading of O’Connor’s theorem. Using these values, the MU
calculated for the RAO field is 409 MU, which is within 8%
of the TPS value of 443 MU. The MUV is improved from
the simpler standard block treatment, but is still outside the
action level for different calculation methods and small
fields.
c. New calculation point
An examination of the point placement in Fig. 8 raised
concerns that the calculation point may be positioned too
close to an interface and may be subject to rebuild-up and
lateral electron disequilibrium. To reduce such effects, the
calculation point was moved to the center of the tumor, as
shown in Fig. 9, and O’Connor’s theorem was applied to
obtain a MUV calculation. The parameters for this calcula-
tion are given in Table XII, for which the MUV was deter-
mined to be 422.8 MU. This MUV is within 4.6% of the
443 MU calculated by the TPS and within the 5% action
level for different calculation methods and small fields given
in Table III.
7. Direct electron case
In this example, an en face 12 MeV electron beam was
used to treat a rib see Fig. 10. A rectangular aperture of 6
10 cm2 in a 1010 cm2 applicator was used at 105 cmMedical Physics, Vol. 38, No. 1, January 2011SSD. The TPS calculated dose distribution was normalized
to a nominal depth of 3 cm and prescribed to deliver 300
cGy to the 97% isodose line.
The output setting was determined according to the equa-
tion,
MU =
D
D0 · Sera,r
· SSDeff + d0 + gSSDeff + d0 
2
. B9
The MUV was calculated using the dose D, derived from the
prescription of 300 cGy /97%=309.3 cGy, and the param-
eters listed in Table XIII. Using these parameters, a value of
345 MU was obtained, which is within 0.9% of the TPS
calculated value of 348, and within the action level of 3% in
Table II for different algorithms, uniform cube phantom, and
modest field shaping.
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